Atomoxetine, sold under the brand name Strattera, is a selective norepinephrine reuptake inhibitor (sNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, cognitive disengagement syndrome (CDS). It may be u + some more technical info including its high affinity for the norepinephrine transporter with minimal direct inhibition of the dopamine transporter in striatal regions, oral bioavailability around 60 to 65 percent in CYP2D6 extensive metabolizers, time to peak plasma concentration about 1 to 2 hours, plasma protein binding approximately 98 percent, primary metabolism via CYP2D6 to 4-hydroxy-atomoxetine and N-desmethyl-atomoxetine, and elimination half-life roughly 5 hours in extensive metabolizers and up to about 24 hours in poor metabolizers; these pharmacokinetic characteristics drive dose adjustments and drug interaction considerations.
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine / Atomoxetine Hydrochloride
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Fluoxetine/ Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Parent: Atomoxetine
Typical analytical control for atomoxetine API targets an assay of at least 98.0 percent and monitors related substances by validated HPLC or LC-MS methods; routinely monitored related compounds include N-desmethyl-atomoxetine (major metabolite), 4-hydroxy-atomoxetine, 4-hydroxy-N-desmethyl-atomoxetine, positional isomers and residual synthetic intermediates. Representative release limits used in supplier specifications are: N-desmethyl-atomoxetine ≤0.30 percent, 4-hydroxy-atomoxetine ≤0.20 percent, 4-hydroxy-N-desmethyl-atomoxetine ≤0.10 percent, individual unspecified impurities typically ≤0.05 to 0.10 percent, and total impurities commonly controlled to ≤1.0 to 2.0 percent depending on the risk assessment and regulatory filing. Residual solvents are controlled per ICH Q3C with class-specific ppm limits and elemental impurities per ICH Q3D with limits in the low ppm range; final product specifications should reference the applicable regulatory monograph and validated stability data.
Atomoxetine is prescribed primarily for the treatment of ADHD to reduce inattention, hyperactivity and impulsivity; it is also used off-label or investigated for related attention disorders such as cognitive disengagement syndrome and may be used as monotherapy or as part of a comprehensive treatment plan.
Atomoxetine is neither a classical stimulant nor a depressant; it is a non-stimulant selective norepinephrine reuptake inhibitor with low abuse potential and a pharmacologic profile distinct from stimulants.
No, atomoxetine is not the same as Ritalin. Ritalin is the brand name for methylphenidate, a central nervous system stimulant with a different mechanism of action, onset of effect, side effect profile and abuse potential.
Weight effects vary by individual. Weight loss is more commonly reported, especially during initial treatment in children, but weight gain can occur in some patients over longer periods. Patients should have weight monitored and discuss changes with their prescriber.
